Generic Name and Formulations:
Estrone sodium sulfate (as estropipate) 5mg; scored tabs.
Indications for OGEN:
Moderate to severe vasomotor symptoms of menopause. Atrophic vaginitis. Osteoporosis prevention. Hypoestrogenism.
Menopause: 0.625–5mg daily, given cyclically (3 weeks on, 1 week off). Osteoporosis prevention (begin therapy soon after menopause): 0.625mg daily, given cyclically (25 days of a 31-day cycle). Hypoestrogenism: 1.25–7.5mg daily for 3 weeks. Repeat course if withdrawal bleeding does not occur within 8–10 days after discontinuing. See literature. Reevaluate periodically.
Breast or estrogen-dependent carcinoma. Undiagnosed abnormal genital bleeding. Thromboembolic disorders. Thrombophlebitis. Pregnancy (Cat.X).
Patients with an intact uterus should almost always receive a progestin to avoid endometrial hyperplasia. Cardiovascular disease. Hepatic dysfunction. Gallbladder disease. Conditions aggravated by fluid retention. Bone disease associated with hypercalcemia. Do initial complete physical and repeat annually (include BP, mammogram, and PAP smear). Discontinue if jaundice or hypertension occurs and at least 2 weeks before surgery associated with thromboembolism. Nursing mothers.
See full labeling. GI upset, breakthrough bleeding, edema, weight changes, mastodynia, hypertension, intolerance to contact lenses.
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Case for Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Pioglitazone May Reduce Cardiovascular, Noncardiovascular Mortality in T2D
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure
- Greater Bone Formation With Teriparatide vs Zoledronic Acid in Osteoporosis